Premature Ejaculation (PE) is one
of the most common sexual dysfunctions, affecting 20%-40% of sexually active
men. There were various definitions of PE by different professional
organizations. However, since the underlying physiopathology of PE was not well
understood, there were no universally accepted definition of PE until the
International Society for Sexual Medicine (ISSM) established
the first evidence-based definition of lifelong PE in 2007. Subsequently,
Waldinger et al. proposed a new classification for PE in 2008, which included
four subtypes: lifelong PE (LPE), acquired PE (APE), natural variable PE
(NVPE), and Premature-Like Ejaculatory Dysfunction (PLED).
In recent years, although a lot
of therapies have been proved to be efficacious in the treatment of PE, most
research has focused on the treatment of LPE, or ignored the different types of
PE. There are few studies concerning the treatment of APE, although Serefoglu
et al. revealed that APE was more severe than other subtypes.
To our knowledge, this is the
first randomised trial to show sertraline monotherapy and a combination of
sildenafil and sertraline in the treatment of APE in patients without concomitant
diseases. Therefore, we conducted this clinical study to evaluate the efficacy
of 50 mg sertraline daily and a combination of 50 mg sildenafil as needed and
50 mg sertraline daily in the treatment of APE in patients without concomitant
diseases.
No comments:
Post a Comment